var data={"title":"Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Acneiform eruption secondary to epidermal growth factor receptor (EGFR) inhibitors</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/contributors\" class=\"contributor contributor_credentials\">Mario E Lacouture, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/contributors\" class=\"contributor contributor_credentials\">Yevgeniy Balagula, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/contributors\" class=\"contributor contributor_credentials\">Maja Mockenhaupt, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 29, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H195039099\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Agents targeting the epidermal growth factor receptor (EGFR)-mediated signalling pathway are increasingly used for the treatment of advanced lung, pancreatic, colorectal, and head and neck cancers [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/1,2\" class=\"abstract_t\">1,2</a>]. They include monoclonal antibodies (eg, <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, <a href=\"topic.htm?path=panitumumab-drug-information\" class=\"drug drug_general\">panitumumab</a>, <a href=\"topic.htm?path=necitumumab-drug-information\" class=\"drug drug_general\">necitumumab</a>, <a href=\"topic.htm?path=pertuzumab-drug-information\" class=\"drug drug_general\">pertuzumab</a>) and small-molecule tyrosine kinase inhibitors (eg, <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a>, <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, <a href=\"topic.htm?path=afatinib-drug-information\" class=\"drug drug_general\">afatinib</a>, <a href=\"topic.htm?path=osimertinib-drug-information\" class=\"drug drug_general\">osimertinib</a>, <a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">lapatinib</a>) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/3\" class=\"abstract_t\">3</a>]. The ability of EGFR inhibitors to block specific molecular pathways driving uncontrolled cellular division in cancer has resulted in a decreased incidence of serious systemic adverse events commonly associated with conventional cytotoxic chemotherapy [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/4\" class=\"abstract_t\">4</a>]. However, cutaneous adverse events to EGFR inhibitors are frequent, due to the abundant expression of EGFR in the skin and adnexal structures [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/5\" class=\"abstract_t\">5</a>]. Cutaneous adverse reactions to EGFR inhibitors include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Acneiform (papulopustular) rash</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Abnormal scalp, facial hair, <span class=\"nowrap\">and/or</span> eyelash growth</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Paronychia with or without pyogenic granulomas</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Telangiectasias </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Xerosis and pruritus </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Xerotic dermatitis</p><p/><p>Acneiform eruption is the prototypical cutaneous adverse reaction associated with all EGFR inhibitors. Acneiform eruption is rarely life-threatening [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/6\" class=\"abstract_t\">6</a>]. However, it affects cosmetically sensitive areas, causes pain and pruritus, and may impair the patient&rsquo;s quality of life and adherence to cancer therapies. In intolerable or severe cases, dose modification or interruption of a potentially life-prolonging therapy may be necessary [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/7\" class=\"abstract_t\">7</a>]. </p><p>The acneiform eruption secondary to EGFR inhibitors will be reviewed in this topic. Other cutaneous adverse reactions to molecularly targeted therapy or conventional chemotherapy agents are discussed separately. (See <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;</a> and <a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">&quot;Cutaneous side effects of conventional chemotherapy agents&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H195039106\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Acneiform eruptions occur in over 80 percent of patients treated with EGFR inhibitors [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/8\" class=\"abstract_t\">8</a>]. Patients of any age may be affected [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/9,10\" class=\"abstract_t\">9,10</a>]. </p><p class=\"headingAnchor\" id=\"H3612236\"><span class=\"h2\">Risk factors</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Potential risk factors for the development of EGFR inhibitor-related acneiform rash include age, gender, skin phototype, UV exposure, smoking, and combination therapy with conventional chemotherapy agents. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with advanced non-small cell lung cancer treated with <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, age &ge;70 is associated with an increased risk of severe (grade &ge;3 (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>)) rash [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/9\" class=\"abstract_t\">9</a>]. In contrast, in patients with metastatic colorectal cancer treated with <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, age &le;70 and male sex are associated with a higher rate of grade 3 eruption [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/10\" class=\"abstract_t\">10</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a retrospective study of patients treated with <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, grade 3 to 4 rash (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>) occurred almost exclusively in patients with skin phototype <span class=\"nowrap\">I/II</span> (<a href=\"image.htm?imageKey=PC%2F60541\" class=\"graphic graphic_table graphicRef60541 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/11\" class=\"abstract_t\">11</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The frequent localization of the acneiform eruption to sun-exposed areas such as the face and the &quot;V&quot; area of the neck and upper chest suggests that UV radiation may act as a cofactor in the development or severity of skin eruption. Pre-clinical data also implicate an EGFR as an important mediator of keratinocyte proliferation and survival in response to exposure UV light. </p><p/><p>Inhibition of EFGR in cultured keratinocytes prior to UVR exposure has been shown to decrease cell survival and enhance <span class=\"nowrap\">apoptosis/necrosis</span> following UV irradiation, compared with cells exposed only to UV radiation [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/12\" class=\"abstract_t\">12</a>]. However, in a randomized trial, the daily application of a sunscreen with a sun protection factor of 60 did not prevent or reduce the severity of the skin reaction [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/13\" class=\"abstract_t\">13</a>]. Nonetheless, sunscreen is recommended because of the potential photosensitivity related to EGFR inhibitors. &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Among patients with non-small cell lung cancer, smoking during therapy with <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a> is associated with a lower incidence of skin eruption [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/14\" class=\"abstract_t\">14</a>]. A possible mechanism is the induction of the liver cytochrome P450 3A4 with subsequent enhanced clearance of the drug [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/14,15\" class=\"abstract_t\">14,15</a>]. This mechanism is supported by the observation that the maximum tolerated dose of erlotinib is increased among active smokers [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/15\" class=\"abstract_t\">15</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a meta-analysis of nine trials (5333 patients), the incidence of grade &ge;3 rash (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>) was higher in patients treated with <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a> in combination with a variety of conventional cytotoxic agents than in patients treated with cetuximab alone [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/16\" class=\"abstract_t\">16</a>]. </p><p/><p class=\"headingAnchor\" id=\"H31702946\"><span class=\"h2\">Relationship between rash and survival</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Several studies have noted an association between acneiform eruption and increased overall response rate or survival, suggesting that the skin eruption may be a surrogate marker for efficacy of EGFR inhibitor therapy [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/17-23\" class=\"abstract_t\">17-23</a>]. In a meta-analysis of 24 trials (3312 patients) of <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a> or <a href=\"topic.htm?path=gefitinib-drug-information\" class=\"drug drug_general\">gefitinib</a> for non-small cell lung cancer, patients who developed a rash had a lower risk of death than patients without rash (hazard ratio [HR] 0.30; 95% CI 0.21&ndash;0.43) and disease progression (HR 0.50; 95% CI 0.41&ndash;0.61) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/24,25\" class=\"abstract_t\">24,25</a>]. </p><p>Similarly, metastatic colorectal cancer patients harboring wild-type <em>KRAS </em>who developed moderate or severe rash when treated with <a href=\"topic.htm?path=panitumumab-drug-information\" class=\"drug drug_general\">panitumumab</a> or <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a> had a significantly prolonged overall survival, progression-free survival, and overall response rate [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/26\" class=\"abstract_t\">26</a>]. In addition, in a small randomized trial, dose escalation of EGFR inhibitors in patients with grade &le;1 rash was associated with an increased response rate to treatment [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/27\" class=\"abstract_t\">27</a>]. Although the strategy for dose escalation based upon the rash grade (&quot;dosing-to-rash&quot;) requires further study before it can be routinely recommended, these observations suggest that acneiform eruption is <strong>not</strong> a contraindication to continued EGFR inhibitor therapy. </p><p class=\"headingAnchor\" id=\"H195039113\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Direct inhibition of the EGFR and induction of an inflammatory response are critical steps in the development of the primary lesion [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/28\" class=\"abstract_t\">28</a>].</p><p class=\"headingAnchor\" id=\"H195039120\"><span class=\"h2\">Direct receptor inhibition</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In the epidermis, the EGFR is preferentially expressed in undifferentiated, actively proliferating basal and suprabasal keratinocytes, outer layers of the hair follicle, and pilosebaceous glands [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Coupled to various intracellular signaling pathways, EGFR plays a critical role in maintaining epidermal homeostasis through regulation of keratinocyte proliferation, differentiation, migration, and survival [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/31\" class=\"abstract_t\">31</a>]. The intracellular signaling pathways may include RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K)-AKT, stress-activated protein kinase, and <span class=\"nowrap\">JAK/STAT</span>.</p><p>Direct receptor inhibition by tyrosine kinase inhibitors or monoclonal antibodies downregulates the level of the phosphorylated EGFR in basal and suprabasal keratinocytes and the outer layer of hair follicles resulting in [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/32-36\" class=\"abstract_t\">32-36</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diminished proliferation of basal keratinocytes evidenced by the reduced expression of the proliferation marker Ki67 and increased expression of the negative growth regulator p27 </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Growth arrest and apoptosis of keratinocytes</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Increased expression of terminal differentiation markers keratin 1 and STAT3 in the basal keratinocytes reflecting premature and accelerated differentiation</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Decreased migration of differentiating keratinocytes through the epidermis due to enhanced cell attachment mediated by increased expression of desmoglein 2</p><p/><p class=\"headingAnchor\" id=\"H195039127\"><span class=\"h2\">Inflammatory response</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Exposure of epithelial cells to EGFR inhibitors induces upregulation of IL-1 and TNF-alpha and increases synthesis of other inflammatory chemokines and cytokines (eg, monocyte chemoattractant protein 1 (CCL-2), RANTES (CCL-5), T-lymphocyte-recruiting CCL-18, CCL-3, CCL27, and CXCL14) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/37\" class=\"abstract_t\">37</a>], resulting in the formation of an early infiltrate of CD45RO<sup>+</sup> T lymphocytes, Langerhans cells, macrophages, and tumor necrosis factor related apoptosis inducing ligand (TRAIL)-positive cells with dendritic morphology [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/28,32,38,39\" class=\"abstract_t\">28,32,38,39</a>]. Keratinocyte-derived cytokines appear to be the major force recruiting macrophages, mast cells and granulocytes [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/37\" class=\"abstract_t\">37</a>]. This hypothesis is supported by the finding that patients treated with <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a> have elevated levels of serum CCL27, compared with normal controls [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/37\" class=\"abstract_t\">37</a>]. The eventual influx of neutrophils contributes to the inflammation manifesting as superficial perifolliculitis or suppurative folliculitis [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/32,39\" class=\"abstract_t\">32,39</a>]. In addition, an increased number of total and highly degranulated mast cells has been demonstrated in lesional skin [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/37\" class=\"abstract_t\">37</a>]. Macrophages may also play an important pathogenetic role, since in mouse models their local depletion resulted in amelioration of cutaneous eruption [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/40\" class=\"abstract_t\">40</a>].</p><p>The inflammatory response also may be secondary to altered growth and differentiation of follicular epithelium, which results in keratotic plugging and rupture of follicular infundibulum and influx of neutrophils [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/39\" class=\"abstract_t\">39</a>]. This theory is supported by the observation that abnormal pilosebaceous units are present in both affected and unaffected skin of patients exposed to EGFR inhibitors [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/38\" class=\"abstract_t\">38</a>]. In mouse models, an initial alteration in hair follicles and pilosebaceous units is followed by inflammatory changes [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/41,42\" class=\"abstract_t\">41,42</a>]. </p><p class=\"headingAnchor\" id=\"H195039134\"><span class=\"h2\">Role of microorganisms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Microorganisms do not appear to contribute to the pathogenesis of the early eruption and the initial pustule is sterile [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/39\" class=\"abstract_t\">39</a>]. However, colonization with <em>Staphylococcus aureus</em> may be seen early in the course of the cutaneous eruption [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/37\" class=\"abstract_t\">37</a>]. Secondary infection with <em>Staphylococcus aureus</em> may have a role in the late phase of the rash, sometimes after several months of therapy [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/43\" class=\"abstract_t\">43</a>]. </p><p>In-vitro investigations demonstrated the ability of <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a> to inhibit the expression of human b-defensin-3, cathelicidin LL37, and ribonuclease 7, which are critical components of the innate antimicrobial defense system. Furthermore, diminished expression of claudin-1, a tight junction protein, is significantly reduced in lesional skin of EGFR inhibitor-treated patients, which may contribute to disruption of the epidermal barrier and increase the risk of cutaneous infections [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/37\" class=\"abstract_t\">37</a>].</p><p>A small retrospective study demonstrated a significantly increased density of <em>Demodex folliculorum</em> in skin biopsies of patients treated with EGFR inhibitors, further supporting the hypothesis that these therapies may impair the skin antimicrobial defenses [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/44\" class=\"abstract_t\">44</a>]. </p><p class=\"headingAnchor\" id=\"H3612515\"><span class=\"h1\">HISTOPATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most frequently affected structures include hair follicles (61 percent), epidermis (52 percent), and sebaceous glands (45 percent) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/38\" class=\"abstract_t\">38</a>]. The two major histopathologic patterns are a superficial perifolliculitis, characterized by neutrophilic infiltrate surrounding the hyperkeratotic <span class=\"nowrap\">and/or</span> ectatic follicular infundibula, and a florid neutrophilic suppurative folliculitis with rupture of the epithelial lining [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/17,45\" class=\"abstract_t\">17,45</a>].</p><p>The stratum corneum is compact and eosinophilic and its normal basket-weave appearance is lost [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/33,46\" class=\"abstract_t\">33,46</a>]. Epidermal atrophy, keratinocyte dysmaturation, and dyskeratosis may be seen [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/47\" class=\"abstract_t\">47</a>]. Other reported alterations include intraepidermal acantholysis, vacuolar degeneration of the basal cell layer, prominent keratin plugs, and lichenoid changes [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/33,39\" class=\"abstract_t\">33,39</a>]. The sebaceous glands are hypoplastic with poorly differentiated sebocytes and keratinocytes [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/38\" class=\"abstract_t\">38</a>]. The histologic alterations of the pilosebaceous units without an inflammatory infiltrate also can be seen in uninvolved skin [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/38\" class=\"abstract_t\">38</a>].</p><p class=\"headingAnchor\" id=\"H195039141\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The primary lesion of the EGFR inhibitor-induced acneiform eruption is a folliculocentric erythematous papule or pustule. Areas rich in sebaceous glands, such as the scalp, face, and particularly the nose, cheeks, nasolabial folds, and perioral region, are most commonly affected (<a href=\"image.htm?imageKey=PC%2F55753\" class=\"graphic graphic_picture graphicRef55753 \">picture 1</a>). The upper trunk and especially the &quot;V&quot; region of the neck and chest also are involved [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/39,48\" class=\"abstract_t\">39,48</a>]. Less frequently, the eruption may extend to the lower trunk, buttocks, and extremities. The palmoplantar surfaces are characteristically spared [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/5\" class=\"abstract_t\">5</a>]. Common associated symptoms include pruritus, pain, irritation, and stinging [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/49\" class=\"abstract_t\">49</a>]. </p><p>The onset of the eruption typically occurs within the first two weeks of therapy but it can occur up to two months after starting the treatment [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/50,51\" class=\"abstract_t\">50,51</a>]. The combination of EGFR inhibitors with other treatment modalities (eg, conventional cytotoxic chemotherapy agents, radiotherapy) may increase the severity of the acneiform eruption [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/16\" class=\"abstract_t\">16</a>]. </p><p class=\"headingAnchor\" id=\"H3611686\"><span class=\"h1\">CLINICAL COURSE</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The acneiform eruption generally evolves through four distinct phases [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/52\" class=\"abstract_t\">52</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>First week &ndash;<strong> </strong>Sensory disturbance (dysesthesia) accompanied by erythema and edema &#160;</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>First to third week &ndash;<strong> </strong>Development of erythematous papules and pustules </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Third to fourth week &ndash;<strong> </strong>Formation of crusts from purulent material and necrotic <span class=\"nowrap\">keratinocytes/debris</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>One month and longer &ndash;<strong> </strong>Persistent erythema with scattered telangiectasias and skin dryness</p><p/><p>The clinical course is characterized by waxing and waning of lesions. Partial or even complete resolution may be seen despite continued EGFR inhibitor therapy [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/50,53,54\" class=\"abstract_t\">50,53,54</a>]. Following the discontinuation of the offending agent, resolution typically occurs in four weeks [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/54,55\" class=\"abstract_t\">54,55</a>].</p><p class=\"headingAnchor\" id=\"H699849676\"><span class=\"h1\">COMPLICATIONS AND SEQUELAE</span></p><p class=\"headingAnchor\" id=\"H699849684\"><span class=\"h2\">Secondary infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although the initial pustules are sterile, secondary infection of the affected skin may occur [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/39\" class=\"abstract_t\">39</a>]. A retrospective analysis of 221 patients treated with <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, <a href=\"topic.htm?path=panitumumab-drug-information\" class=\"drug drug_general\">panitumumab</a>, <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, or <a href=\"topic.htm?path=lapatinib-drug-information\" class=\"drug drug_general\">lapatinib</a> found that 38 percent developed infections with bacteria, dermatophytes, or viruses [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/56\" class=\"abstract_t\">56</a>]. <em>Staphylococcus aureus</em> was isolated from approximately 60 percent of infected lesions. Staphylococcal bacteremia has been reported in patients with severe skin toxicity induced by erlotinib [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/57,58\" class=\"abstract_t\">57,58</a>]. A 2014 meta-analysis of 26 randomized trials (14,066 patients) reported an increased risk for severe infections in patients treated with anti-EGFR monoclonal antibodies (relative risk 1.34, 95% CI 1.10-1.62) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/59\" class=\"abstract_t\">59</a>].</p><p class=\"headingAnchor\" id=\"H699849441\"><span class=\"h2\">Cutaneous sequelae</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Long-term cutaneous sequelae of EGFR inhibitor-induced acneiform rash include postinflammatory hyperpigmentation, telangiectasias, and erythema [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/60,61\" class=\"abstract_t\">60,61</a>].</p><p>Postinflammatory hyperpigmentation is typically a late adverse event, manifesting after several months of treatment. Postinflammatory hyperpigmentation occurs most often in patients with dark skin phototypes (<a href=\"image.htm?imageKey=PC%2F60541\" class=\"graphic graphic_table graphicRef60541 \">table 2</a>) and can be exacerbated by excessive UV radiation exposure [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/61\" class=\"abstract_t\">61</a>]. Topical <a href=\"topic.htm?path=hydroquinone-drug-information\" class=\"drug drug_general\">hydroquinone</a> 4% cream may be used in an attempt to diminish the degree of hyperpigmentation [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/60\" class=\"abstract_t\">60</a>]. </p><p>Dilated superficial capillaries and erythema may be observed in areas previously affected by the acneiform eruption one to two months after treatment. The initiating event in the development of telangiectasias could be the loss of structural support secondary to connective tissue destruction or the proliferation of endothelial cells in areas of keratinocyte necrosis that are present in follicular pustules [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/28\" class=\"abstract_t\">28</a>]. Pulsed dye laser and intense pulsed light may be utilized to treat telangiectasias. (See <a href=\"topic.htm?path=laser-and-light-therapy-for-cutaneous-vascular-lesions#H10061370\" class=\"medical medical_review\">&quot;Laser and light therapy for cutaneous vascular lesions&quot;, section on 'Telangiectasias and the red face'</a>.)</p><p class=\"headingAnchor\" id=\"H699849637\"><span class=\"h2\">Impact on patients&rsquo; quality of life</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptoms such as pain, pruritus, burning, and irritation are observed in approximately 60 percent of patients with EGFR inhibitor-induced acneiform eruption and can negatively affect the quality of life (QoL) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/55,62\" class=\"abstract_t\">55,62</a>]. A retrospective study examined the data from 67 patients who had completed the Skindex-16 (a self-reported, dermatology-specific QoL questionnaire) at the time of their initial visit for skin reaction to EGFR inhibitors [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/49\" class=\"abstract_t\">49</a>]. A positive correlation was found between rash severity and median scores for symptoms, emotions, and function, with the highest score reported for the emotions domain. </p><p class=\"headingAnchor\" id=\"H195039162\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H3612688\"><span class=\"h2\">Clinical</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of acneiform eruption in patients receiving EGFR inhibitor therapy is usually straightforward, based upon the morphology and distribution of the rash (eg, erythematous follicular papules and pustules in areas rich in sebaceous glands) (<a href=\"image.htm?imageKey=PC%2F55753\" class=\"graphic graphic_picture graphicRef55753 \">picture 1</a>). </p><p class=\"headingAnchor\" id=\"H195039171\"><span class=\"h2\">Grading of severity</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although not always performed in clinical practice, grading the severity of the acneiform eruption is important in guiding the approach to management. In clinical trials and in some oncology practices, the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) is the most commonly employed scale to assess the severity of cutaneous adverse reactions to cancer treatment (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/63,64\" class=\"abstract_t\">63,64</a>]. However, the CTCAE scale (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>), which is based upon the body surface area involvement and symptoms, may not capture specific features of the acneiform rash (eg, involvement of cosmetically sensitive areas, <span class=\"nowrap\">subacute/chronic</span> course) and does not incorporate the patient&rsquo;s perception of severity [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/65,66\" class=\"abstract_t\">65,66</a>]. </p><p class=\"headingAnchor\" id=\"H195039178\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of EGFR inhibitor-induced acneiform eruption includes acneiform eruptions induced by other drugs and other uncommon papulopustular eruptions. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Drug-induced acne</strong> &ndash; Drug-induced acne typically presents with a monomorphous inflammatory papular eruption involving the trunk (<a href=\"image.htm?imageKey=DERM%2F86994%7EDERM%2F86995\" class=\"graphic graphic_picture graphicRef86994 graphicRef86995 \">picture 2A-B</a>). Medications associated with drug-induced acne are listed in the table (<a href=\"image.htm?imageKey=PC%2F76762\" class=\"graphic graphic_table graphicRef76762 \">table 3</a>) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/67\" class=\"abstract_t\">67</a>]. (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris#H28\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris&quot;, section on 'Drug-induced acne'</a>.)</p><p/><p>Other anticancer agents associated with an acneiform eruption include [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/68-71\" class=\"abstract_t\">68-71</a>]: &#160;</p><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Inhibitors of mammalian target of rapamycin (mTOR) &ndash; <a href=\"topic.htm?path=sirolimus-drug-information\" class=\"drug drug_general\">sirolimus</a>, <a href=\"topic.htm?path=tacrolimus-drug-information\" class=\"drug drug_general\">tacrolimus</a>, <a href=\"topic.htm?path=everolimus-drug-information\" class=\"drug drug_general\">everolimus</a>, and <a href=\"topic.htm?path=temsirolimus-drug-information\" class=\"drug drug_general\">temsirolimus</a> </p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Multikinase inhibitors such as <a href=\"topic.htm?path=sunitinib-drug-information\" class=\"drug drug_general\">sunitinib</a>, <a href=\"topic.htm?path=sorafenib-drug-information\" class=\"drug drug_general\">sorafenib</a>, <a href=\"topic.htm?path=axitinib-drug-information\" class=\"drug drug_general\">axitinib</a>, <a href=\"topic.htm?path=pazopanib-drug-information\" class=\"drug drug_general\">pazopanib</a>, <a href=\"topic.htm?path=regorafenib-drug-information\" class=\"drug drug_general\">regorafenib</a>, and <a href=\"topic.htm?path=cabozantinib-drug-information\" class=\"drug drug_general\">cabozantinib</a> &#160;</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>MEK inhibitors <a href=\"topic.htm?path=trametinib-drug-information\" class=\"drug drug_general\">trametinib</a> and <a href=\"topic.htm?path=cobimetinib-drug-information\" class=\"drug drug_general\">cobimetinib</a></p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pityrosporum folliculitis</strong> &ndash; Pityrosporum folliculitis is a skin infection caused by yeasts of the genus <em>Malassezia</em> and characterized by a monomorphous eruption of papules and pustules on the upper trunk or arms (<a href=\"image.htm?imageKey=DERM%2F86998%7EDERM%2F86997\" class=\"graphic graphic_picture graphicRef86998 graphicRef86997 \">picture 3A-B</a>). Characteristic budding yeasts are detected on histologic examination of a skin biopsy after treatment with potassium hydroxide. (See <a href=\"topic.htm?path=invasive-malassezia-infections#H6\" class=\"medical medical_review\">&quot;Invasive Malassezia infections&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Tinea barbae</strong> &ndash; Tinea (sycosis) barbae is a skin infection caused by dermatophytes of the genus <em>Trichophyton</em> occurring predominantly in men. The superficial type presents with papules and pustules in the beard and mustache area (<a href=\"image.htm?imageKey=DERM%2F86999%7EDERM%2F87000\" class=\"graphic graphic_picture graphicRef86999 graphicRef87000 \">picture 4A-B</a>). A potassium hydroxide preparation shows the segmented hyphae and arthrospores characteristic of dermatophyte infections (<a href=\"image.htm?imageKey=DERM%2F60102\" class=\"graphic graphic_picture graphicRef60102 \">picture 5</a>). (See <a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">&quot;Dermatophyte (tinea) infections&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Eosinophilic folliculitis </strong>&ndash; Eosinophilic folliculitis is a pruritic eruption most commonly occurring in HIV-infected patients and presenting with recurrent crops of follicular papules and pustules predominantly involving the head, neck, and upper trunk (<a href=\"image.htm?imageKey=DERM%2F54404%7EDERM%2F87125\" class=\"graphic graphic_picture graphicRef54404 graphicRef87125 \">picture 6A-B</a>). Peripheral eosinophilia is often present. Histology reveals infiltration of eosinophils into hair follicles and perifollicular areas (<a href=\"image.htm?imageKey=PC%2F78005%7EPC%2F67192\" class=\"graphic graphic_picture graphicRef78005 graphicRef67192 \">picture 7A-B</a>). (See <a href=\"topic.htm?path=hiv-associated-eosinophilic-folliculitis\" class=\"medical medical_review\">&quot;HIV-associated eosinophilic folliculitis&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H195039192\"><span class=\"h1\">MANAGEMENT</span></p><p class=\"headingAnchor\" id=\"H29755924\"><span class=\"h2\">General principles</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of the acneiform eruption should be individualized for each patient, based upon the type, severity, and location of the lesions, and the necessity of continuing treatment with EGFR inhibitors. Management in consultation with a dermatologist is suggested for most patients, and particularly if the skin reaction does not improve within two weeks of treatment, is severe (grade 3 to 4 (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>)), or has atypical appearance or distribution. (See <a href=\"#H195039141\" class=\"local\">'Clinical manifestations'</a> above.) </p><p>Given the paucity of clinical trials, the treatment of EGFR inhibitor-induced acneiform eruption is largely based upon clinical experience, consensus statements, and local guidelines [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/72-75\" class=\"abstract_t\">72-75</a>]. Treatment options include topical and systemic corticosteroids, topical and systemic antibiotics, and oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/52,76\" class=\"abstract_t\">52,76</a>]. The choice and progression of treatment is generally guided by the severity of the skin eruption and response to initial therapy (<a href=\"image.htm?imageKey=DERM%2F87010\" class=\"graphic graphic_algorithm graphicRef87010 \">algorithm 1</a>). Grading the severity of rash is discussed above. (See <a href=\"#H195039171\" class=\"local\">'Grading of severity'</a> above.) </p><p class=\"headingAnchor\" id=\"H699849803\"><span class=\"h2\">Treatment of pruritus</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Oral H1 antihistamines, including sedating (eg, <a href=\"topic.htm?path=diphenhydramine-drug-information\" class=\"drug drug_general\">diphenhydramine</a>, <a href=\"topic.htm?path=hydroxyzine-drug-information\" class=\"drug drug_general\">hydroxyzine</a>, <a href=\"topic.htm?path=doxepin-drug-information\" class=\"drug drug_general\">doxepin</a>) or nonsedating agents (eg, <a href=\"topic.htm?path=cetirizine-drug-information\" class=\"drug drug_general\">cetirizine</a>, <a href=\"topic.htm?path=fexofenadine-drug-information\" class=\"drug drug_general\">fexofenadine</a>, <a href=\"topic.htm?path=loratadine-drug-information\" class=\"drug drug_general\">loratadine</a>), may be beneficial for patients with pruritus [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/55,72\" class=\"abstract_t\">55,72</a>]. In a clinical trial, <a href=\"topic.htm?path=aprepitant-drug-information\" class=\"drug drug_general\">aprepitant</a> (a neurokinin 1 receptor antagonist) was effective in reducing pruritus intensity by &gt;80 percent in 41 of 45 patients treated with EGFR and TK inhibitors [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/77\" class=\"abstract_t\">77</a>]. Pruritus did not recur in 87 percent of patients during the 90-day study period. However, aprepitant should be used with caution in patients receiving <a href=\"topic.htm?path=erlotinib-drug-information\" class=\"drug drug_general\">erlotinib</a>, since aprepitant-induced inhibition of the liver cytochrome P450 3A4 may increase the trough levels of erlotinib [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/78\" class=\"abstract_t\">78</a>]. </p><p>GABA agonists such as <a href=\"topic.htm?path=gabapentin-drug-information\" class=\"drug drug_general\">gabapentin</a> and <a href=\"topic.htm?path=pregabalin-drug-information\" class=\"drug drug_general\">pregabalin</a> may be tried if oral antihistamines are ineffective. Evidence of benefit in patients with acneiform eruption secondary to EGFR inhibitors is limited [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/79\" class=\"abstract_t\">79</a>], but they are used to treat other forms of chronic pruritus. (See <a href=\"topic.htm?path=pruritus-overview-of-management#H8354445\" class=\"medical medical_review\">&quot;Pruritus: Overview of management&quot;, section on 'Anticonvulsants'</a>.)</p><p class=\"headingAnchor\" id=\"H29755685\"><span class=\"h2\">Patients with grade 1 rash</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with grade 1 rash (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>), we usually suggest topical corticosteroids and topical antibiotics (<a href=\"image.htm?imageKey=DERM%2F87010\" class=\"graphic graphic_algorithm graphicRef87010 \">algorithm 1</a>). We typically use low potency topical corticosteroids (groups six and seven (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 4</a>)) plus <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> 1% gel twice a day for four weeks. <a href=\"topic.htm?path=erythromycin-drug-information\" class=\"drug drug_general\">Erythromycin</a> 3% gel or cream or <a href=\"topic.htm?path=metronidazole-drug-information\" class=\"drug drug_general\">metronidazole</a> 0.75% to 1% <span class=\"nowrap\">cream/gel</span> also may be used.</p><p>We generally reassess patients after four weeks of treatment. If the acneiform eruption has not improved or has worsened, patients are treated in the same way as those with grade 2 rash.</p><p>The use of topical corticosteroids and antibiotics for the treatment of the acneiform eruption has not been evaluated in randomized trials. Our suggestion for their use is based upon case series and case reports and clinical experience [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/72,76,80-84\" class=\"abstract_t\">72,76,80-84</a>].</p><p class=\"headingAnchor\" id=\"H29755709\"><span class=\"h2\">Patients with grade 2 rash</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with grade 2 rash (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>), we suggest topical corticosteroids and oral tetracyclines (<a href=\"image.htm?imageKey=DERM%2F87010\" class=\"graphic graphic_algorithm graphicRef87010 \">algorithm 1</a>). We use low potency topical corticosteroids (group six (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 4</a>)) twice a day on the face and neck and <a href=\"topic.htm?path=fluocinonide-drug-information\" class=\"drug drug_general\">fluocinonide</a> 0.05% cream twice a day on chest and back for at least four weeks and either <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> 100 mg or <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> 100 mg twice per day for four to six weeks. </p><p>If a patient with grade 2 rash is already on an oral <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a>, an alternative antibiotic such as a first-generation oral cephalosporin (eg, <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">cephalexin</a> 500 mg twice per day, <a href=\"topic.htm?path=cefadroxil-drug-information\" class=\"drug drug_general\">cefadroxil</a> 500 mg twice per day) or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (<a href=\"topic.htm?path=trimethoprim-drug-information\" class=\"drug drug_general\">trimethoprim</a> 160 <span class=\"nowrap\">mg/sulfamethoxazole</span> 800 mg twice per day) can be given for four weeks. If viral or bacterial superinfection is suspected, cultures of exudates should be obtained prior to the initiation of the antibiotic to determine appropriate antimicrobial therapy.</p><p>We generally reassess patients after two weeks of treatment. If no improvement or worsening is noted after two weeks of treatment, patients are treated in the same way as those with grade &ge;3 rash. &#160;</p><p>The use of topical corticosteroids and oral antibiotics for the treatment of the acneiform eruption has not been evaluated in randomized trials. Their use is based upon case series and case reports and clinical experience [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/72,76,80-84\" class=\"abstract_t\">72,76,80-84</a>]. </p><p class=\"headingAnchor\" id=\"H662500\"><span class=\"h2\">Patients with grade &ge;3 rash</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with grade &ge;3 (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>) or intolerable grade 2 rash, or rash that interferes with self-care activities of daily living or impairs the quality of life, dose modification of EGFR inhibitors may be warranted. Modification of EGFR inhibitor therapy should occur according to the instructions provided in the prescribing information for the particular agent [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/52,76\" class=\"abstract_t\">52,76</a>]. Dose modification is maintained until improvement to grade &le;2. </p><p>In addition to dose modification of EGFR inhibitor therapy, we suggest treatment with oral antibiotics plus a short course of systemic corticosteroids (<a href=\"image.htm?imageKey=DERM%2F87010\" class=\"graphic graphic_algorithm graphicRef87010 \">algorithm 1</a>). Oral <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> 100 mg or <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> 100 mg is given twice a day for at least four weeks. First-generation oral cephalosporins (eg, <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">cephalexin</a> 500 mg twice per day, <a href=\"topic.htm?path=cefadroxil-drug-information\" class=\"drug drug_general\">cefadroxil</a> 500 mg twice per day) or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> (<a href=\"topic.htm?path=trimethoprim-drug-information\" class=\"drug drug_general\">trimethoprim</a> 160 <span class=\"nowrap\">mg/sulfamethoxazole</span> 800 <span class=\"nowrap\">mg/twice</span> per day) given for four weeks can be used as alternatives when patients do not benefit from <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> antibiotics or have a culture-proven infection with organisms resistant to tetracycline antibiotics. Oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 0.5 <span class=\"nowrap\">mg/kg</span> up to a maximum of 40 mg per day is given for seven days. </p><p>Improvement should be noted within two weeks. If a viral or bacterial superinfection is suspected, cultures of exudates should be obtained prior to the initiation of the antibiotic treatment to determine appropriate antimicrobial therapy. </p><p>Oral corticosteroids for the treatment of severe acneiform eruption have not been evaluated in randomized trials and their use is based upon their antiinflammatory properties and clinical experience. &#160;</p><p class=\"headingAnchor\" id=\"H27163434\"><span class=\"h3\">Refractory grade &ge;3 rash</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with grade &ge;3 rash that does not improve with the regimen described above, low-dose <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> (20 to 30 mg per day) may be tried [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/80\" class=\"abstract_t\">80</a>]. Oral tetracyclines are discontinued before initiating oral isotretinoin. Improvement is generally evident within four weeks [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/85\" class=\"abstract_t\">85</a>]; therapy is continued for at least two months after patients resume EGFR inhibitor at regular dose.</p><p><a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">Isotretinoin</a> may aggravate some EGFR inhibitor adverse effects such as skin dryness, cheilitis, or photosensitivity. Skin dryness and cheilitis can be alleviated by the application of alcohol-free emollients multiple times per day. Patients with increased photosensitivity should adopt sun protection measures, which include limiting the exposure to the sun, wearing protective clothing, and regular use of sunscreens with SPF &ge;30. (See <a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris#H9\" class=\"medical medical_review\">&quot;Oral isotretinoin therapy for acne vulgaris&quot;, section on 'Mucocutaneous side effects'</a>.)</p><p>If no improvement or worsening is noted despite dose modification, treatment with systemic antibiotics and systemic corticosteroids, or oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a>, interruption or discontinuation of EGFR inhibitor treatment may be necessary. Decisions regarding interruption or discontinuation of EGFR inhibitor therapy must involve the patient, the patient&rsquo;s oncologist, and the patient&rsquo;s dermatologist; the potential risks and benefits and the patient&rsquo;s values and preferences must be considered. </p><p>The evidence for efficacy of oral <a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> for severe acneiform eruption is limited to single case reports and small case series [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/84-87\" class=\"abstract_t\">84-87</a>]. Indirect evidence of efficacy is derived from studies of treatment of acne vulgaris. (See <a href=\"topic.htm?path=treatment-of-acne-vulgaris#H3169690\" class=\"medical medical_review\">&quot;Treatment of acne vulgaris&quot;, section on 'Oral isotretinoin'</a>.)</p><p class=\"headingAnchor\" id=\"H52639361\"><span class=\"h1\">PREVENTION</span></p><p class=\"headingAnchor\" id=\"H52639369\"><span class=\"h2\">General measures</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Before initiating treatment with EGFR inhibitors, patients should be educated about adopting general skin care measures, which include [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/66\" class=\"abstract_t\">66</a>]: </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Regularly using a broad-spectrum <span class=\"nowrap\">(UVA/UVB)</span> sunscreen with SPF &ge;15 with inorganic ingredients (<a href=\"topic.htm?path=zinc-oxide-drug-information\" class=\"drug drug_general\">zinc oxide</a>, titanium dioxide)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Limiting excessive sun exposure</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Using thick, alcohol-free emollients twice daily</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoiding over the counter anti-acne medications and alcohol-based skin care products</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reducing the frequency and duration of hot showers</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Using <span class=\"nowrap\">tepid/lukewarm</span> water for bathing </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoiding antibacterial or perfumed soaps and detergents</p><p/><p class=\"headingAnchor\" id=\"H52639376\"><span class=\"h2\">Preemptive therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We suggest prophylactic oral tetracyclines in conjunction with topical corticosteroids for patients initiating treatment with EGFR inhibitors. Treatment is started on the same day as EGFR inhibitor therapy. We typically use <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> 100 mg twice a day or <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> 100 mg daily for six to eight weeks. A low-potency topical corticosteroid (eg, <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a> 2.5%, <a href=\"topic.htm?path=alclometasone-drug-information\" class=\"drug drug_general\">alclometasone</a> 0.05% cream) is applied twice daily to the face and chest. </p><p>The efficacy of oral tetracyclines for the prevention of the acneiform eruption has been evaluated in two meta-analyses.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a 2012 meta-analysis of four placebo-controlled trials [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/88-91\" class=\"abstract_t\">88-91</a>] including 351 patients, patients who initiated prophylactic treatment with a <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> on the same day or the day before initiating EGFR inhibitor therapy had a decreased incidence of moderate to severe (grade &ge;2 (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>)) folliculitis (combined odds ratio 0.19, 95% CI 0.12-0.31) [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/92\" class=\"abstract_t\">92</a>]. However, the benefit was lost after discontinuation of treatment. The incidence of mild (grade 1 (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>)) folliculitis was not changed by prophylactic tetracyclines. The data were insufficient to determine the optimal treatment regimen and duration. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A subsequent 2016 meta-analysis including nine randomized trials and four observational studies (1073 patients) confirmed the benefit of preemptive antibiotic therapy for the prevention of the acneic eruption [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/93\" class=\"abstract_t\">93</a>]. In this meta-analysis, prophylactic treatment with <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> or <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> reduced by approximately 50 percent the risk of developing a skin rash of any grade (OR 0.54, 95% CI 0.40-0.73) and by approximately 70 percent the risk of grade 2 or 3 rash (OR 0.36, 95% CI 0.22-0.60). The results were similar when the analysis was restricted to randomized trials. &#160;</p><p/><p>The efficacy of topical treatments alone or in conjunction with oral antibiotics for the prevention of acneiform eruption has not been adequately evaluated. In a randomized trial of patients initiating <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a> therapy with or without prophylactic <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a>, <a href=\"topic.htm?path=tazarotene-drug-information\" class=\"drug drug_general\">tazarotene</a> 0.05% cream applied to one side of the face was not effective in preventing the acneiform eruption when used as a single agent and provided little benefit beyond that seen with minocycline alone when used in combination with oral minocycline [<a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/88\" class=\"abstract_t\">88</a>]. In addition, tazarotene was associated with significant skin irritation. &#160;</p><p class=\"headingAnchor\" id=\"H195039241\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The acneiform (papulopustular) eruption is the prototypical cutaneous adverse reaction to treatment with EGFR inhibitors. It occurs in over 80 percent of patients and is more frequent in older patients and in patients with light skin phototypes (<a href=\"image.htm?imageKey=PC%2F60541\" class=\"graphic graphic_table graphicRef60541 \">table 2</a>). (See <a href=\"#H195039099\" class=\"local\">'Introduction'</a> above and <a href=\"#H195039106\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The eruption develops mainly in areas rich in sebaceous glands (eg, scalp, face, upper trunk) within the first two weeks of therapy (<a href=\"image.htm?imageKey=PC%2F55753\" class=\"graphic graphic_picture graphicRef55753 \">picture 1</a>). Erythematous papules and pustules evolve to crusted lesions and eventually resolve leaving persistent erythema, telangiectasias, and skin dryness. Bacterial superinfection may occur. (See <a href=\"#H195039141\" class=\"local\">'Clinical manifestations'</a> above and <a href=\"#H3611686\" class=\"local\">'Clinical course'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of acneiform eruption in patients receiving EGFR inhibitor therapy is usually straightforward, based upon the morphology and distribution of the skin lesions (eg, erythematous and follicular papules or pustules in areas rich in sebaceous glands with sparing of palmoplantar surfaces) (<a href=\"image.htm?imageKey=PC%2F55753\" class=\"graphic graphic_picture graphicRef55753 \">picture 1</a>). The severity is graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 5.0 (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>). (See <a href=\"#H195039162\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest prophylactic oral tetracyclines in conjunction with topical corticosteroids for patients initiating treatment with EGFR inhibitors (<a href=\"grade.htm?i=4\" class=\"grade\">Grade 2A</a>). Treatment is started on the same day as EGFR inhibitor therapy. We typically use <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> 100 mg twice a day or <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> 100 mg daily for six to eight weeks; low-potency corticosteroids such as <a href=\"topic.htm?path=hydrocortisone-drug-information\" class=\"drug drug_general\">hydrocortisone</a> 2.5% or <a href=\"topic.htm?path=alclometasone-drug-information\" class=\"drug drug_general\">alclometasone</a> 0.05% cream are applied twice a day. (See <a href=\"#H52639376\" class=\"local\">'Preemptive therapy'</a> above.) </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with grade 1 rash (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>), we suggest topical corticosteroids with or without topical antibiotics (<a href=\"image.htm?imageKey=DERM%2F87010\" class=\"graphic graphic_algorithm graphicRef87010 \">algorithm 1</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We use low potency topical corticosteroids (group six (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 4</a>)) twice a day for four weeks and <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> 1% gel twice a day for four weeks. (See <a href=\"#H29755685\" class=\"local\">'Patients with grade 1 rash'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with grade 2 rash (<a href=\"image.htm?imageKey=ONC%2F67786\" class=\"graphic graphic_table graphicRef67786 \">table 1</a>) who are not taking prophylactic tetracyclines, we suggest topical corticosteroids and oral <a href=\"topic.htm?path=tetracycline-drug-information\" class=\"drug drug_general\">tetracycline</a> antibiotics (<a href=\"image.htm?imageKey=DERM%2F87010\" class=\"graphic graphic_algorithm graphicRef87010 \">algorithm 1</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We use low potency topical corticosteroids (group six (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 4</a>)) twice a day for four weeks and either <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> 100 mg or <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> 100 mg orally twice a day for four weeks. First-generation oral cephalosporins (eg, <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">cephalexin</a>, <a href=\"topic.htm?path=cefadroxil-drug-information\" class=\"drug drug_general\">cefadroxil</a>) or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> can be used as alternative antibiotics for patients who are taking prophylactic tetracyclines or do not benefit from tetracyclines. (See <a href=\"#H29755709\" class=\"local\">'Patients with grade 2 rash'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with grade &ge;3 rash who are not taking prophylactic tetracyclines, we suggest treatment with oral tetracyclines plus a short course of systemic corticosteroids in addition to EGFR inhibitor dose modification (<a href=\"image.htm?imageKey=DERM%2F87010\" class=\"graphic graphic_algorithm graphicRef87010 \">algorithm 1</a>) (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). We use either <a href=\"topic.htm?path=doxycycline-drug-information\" class=\"drug drug_general\">doxycycline</a> 100 mg or <a href=\"topic.htm?path=minocycline-drug-information\" class=\"drug drug_general\">minocycline</a> 100 mg orally twice a day for at least four weeks and <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 0.5 <span class=\"nowrap\">mg/kg</span> orally once per day for seven days. First-generation oral cephalosporins (eg, <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">cephalexin</a>, <a href=\"topic.htm?path=cefadroxil-drug-information\" class=\"drug drug_general\">cefadroxil</a>) or <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a> can be used as alternative antibiotics for patients who are taking prophylactic tetracyclines or do not benefit from tetracyclines. (See <a href=\"#H662500\" class=\"local\">'Patients with grade &ge;3 rash'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/1\" class=\"nounderline abstract_t\">Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006; 33:369.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/2\" class=\"nounderline abstract_t\">Li S, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7:301.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/3\" class=\"nounderline abstract_t\">Curry JL, Torres-Cabala CA, Kim KB, et al. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol 2014; 53:376.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/4\" class=\"nounderline abstract_t\">Vokes EE, Chu E. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers. Oncology (Williston Park) 2006; 20:15.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/5\" class=\"nounderline abstract_t\">Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol 2007; 56:317.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/6\" class=\"nounderline abstract_t\">Jatoi A, Nguyen PL. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Oncologist 2008; 13:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/7\" class=\"nounderline abstract_t\">Boone SL, Rademaker A, Liu D, et al. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 2007; 72:152.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/8\" class=\"nounderline abstract_t\">P&eacute;rez-Soler R, Delord JP, Halpern A, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist 2005; 10:345.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/9\" class=\"nounderline abstract_t\">Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26:2350.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/10\" class=\"nounderline abstract_t\">Jatoi A, Green EM, Rowland KM Jr, et al. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77:120.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/11\" class=\"nounderline abstract_t\">Luu M, Boone SL, Patel J, et al. Higher severity grade of erlotinib-induced rash is associated with lower skin phototype. Clin Exp Dermatol 2011; 36:733.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/12\" class=\"nounderline abstract_t\">Peus D, Vasa RA, Meves A, et al. UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival. Photochem Photobiol 2000; 72:135.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/13\" class=\"nounderline abstract_t\">Jatoi A, Thrower A, Sloan JA, et al. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4). Oncologist 2010; 15:1016.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/14\" class=\"nounderline abstract_t\">Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res 2006; 12:2166.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/15\" class=\"nounderline abstract_t\">Hughes AN, O'Brien ME, Petty WJ, et al. Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers. J Clin Oncol 2009; 27:1220.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/16\" class=\"nounderline abstract_t\">Balagula Y, Wu S, Su X, Lacouture ME. The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis. Ann Oncol 2011; 22:2366.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/17\" class=\"nounderline abstract_t\">Agero AL, Dusza SW, Benvenuto-Andrade C, et al. Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 2006; 55:657.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/18\" class=\"nounderline abstract_t\">Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/19\" class=\"nounderline abstract_t\">Perez-Soler R. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer. Clin Lung Cancer 2006; 8 Suppl 1:S7.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/20\" class=\"nounderline abstract_t\">Wacker B, Nagrani T, Weinberg J, et al. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007; 13:3913.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/21\" class=\"nounderline abstract_t\">Per&eacute;z-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/22\" class=\"nounderline abstract_t\">Fiala O, Pesek M, Finek J, et al. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice. Neoplasma 2013; 60:26.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/23\" class=\"nounderline abstract_t\">Stintzing S, Kapaun C, Laubender RP, et al. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 2013; 132:236.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/24\" class=\"nounderline abstract_t\">Petrelli F, Borgonovo K, Cabiddu M, et al. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 2012; 78:8.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/25\" class=\"nounderline abstract_t\">Liu HB, Wu Y, Lv TF, et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 2013; 8:e55128.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/26\" class=\"nounderline abstract_t\">Petrelli F, Borgonovo K, Barni S. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 2013; 8:173.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/27\" class=\"nounderline abstract_t\">Van Cutsem E, Tejpar S, Vanbeckevoort D, et al. Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 2012; 30:2861.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/28\" class=\"nounderline abstract_t\">Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/29\" class=\"nounderline abstract_t\">Nanney LB, Stoscheck CM, King LE Jr, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990; 94:742.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/30\" class=\"nounderline abstract_t\">Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol 1984; 83:385.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/31\" class=\"nounderline abstract_t\">Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/32\" class=\"nounderline abstract_t\">Han SS, Lee M, Park GH, et al. Investigation of papulopustular eruptions caused by cetuximab treatment shows altered differentiation markers and increases in inflammatory cytokines. Br J Dermatol 2010; 162:371.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/33\" class=\"nounderline abstract_t\">Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/34\" class=\"nounderline abstract_t\">Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20:4292.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/35\" class=\"nounderline abstract_t\">Rodeck U, Jost M, Kari C, et al. EGF-R dependent regulation of keratinocyte survival. J Cell Sci 1997; 110 ( Pt 2):113.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/36\" class=\"nounderline abstract_t\">Lorch JH, Klessner J, Park JK, et al. Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem 2004; 279:37191.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/37\" class=\"nounderline abstract_t\">Lichtenberger BM, Gerber PA, Holcmann M, et al. Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 2013; 5:199ra111.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/38\" class=\"nounderline abstract_t\">Guttman-Yassky E, Mita A, De Jonge M, et al. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010; 46:2010.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/39\" class=\"nounderline abstract_t\">Busam KJ, Capodieci P, Motzer R, et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/40\" class=\"nounderline abstract_t\">Mascia F, Lam G, Keith C, et al. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy. Sci Transl Med 2013; 5:199ra110.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/41\" class=\"nounderline abstract_t\">Murillas R, Larcher F, Conti CJ, et al. Expression of a dominant negative mutant of epidermal growth factor receptor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995; 14:5216.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/42\" class=\"nounderline abstract_t\">Surguladze D, Deevi D, Claros N, et al. Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res 2009; 69:5643.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/43\" class=\"nounderline abstract_t\">Amitay-Laish I, David M, Stemmer SM. Staphylococcus coagulase-positive skin inflammation associated with epidermal growth factor receptor-targeted therapy: an early and a late phase of papulopustular eruptions. Oncologist 2010; 15:1002.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/44\" class=\"nounderline abstract_t\">Gerber PA, Kukova G, Buhren BA, Homey B. Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors. Dermatology 2011; 222:144.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/45\" class=\"nounderline abstract_t\">Brodell LA, Hepper D, Lind A, et al. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J Cutan Pathol 2013; 40:865.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/46\" class=\"nounderline abstract_t\">Malik SN, Siu LL, Rowinsky EK, et al. Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients. Clin Cancer Res 2003; 9:2478.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/47\" class=\"nounderline abstract_t\">Nardone B, Nicholson K, Newman M, et al. Histopathologic and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16:4452.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/48\" class=\"nounderline abstract_t\">Ro&eacute; E, Garc&iacute;a Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55:429.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/49\" class=\"nounderline abstract_t\">Joshi SS, Ortiz S, Witherspoon JN, et al. Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life. Cancer 2010; 116:3916.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/50\" class=\"nounderline abstract_t\">Jacot W, Bessis D, Jorda E, et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/51\" class=\"nounderline abstract_t\">de Noronha e Menezes NM, Lima R, Moreira A, et al. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients. Eur J Dermatol 2009; 19:248.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/52\" class=\"nounderline abstract_t\">Lynch TJ Jr, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007; 12:610.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/53\" class=\"nounderline abstract_t\">Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/54\" class=\"nounderline abstract_t\">Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001; 19:3267.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/55\" class=\"nounderline abstract_t\">Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 2009; 4:107.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/56\" class=\"nounderline abstract_t\">Eilers RE Jr, Gandhi M, Patel JD, et al. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 2010; 102:47.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/57\" class=\"nounderline abstract_t\">Li J, Peccerillo J, Kaley K, Saif MW. Staphylococcus aureus bacteremia related with erlotinib skin toxicity in a patient with pancreatic cancer. JOP 2009; 10:338.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/58\" class=\"nounderline abstract_t\">Grenader T, Gipps M, Goldberg A. Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 2008; 9:59.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/59\" class=\"nounderline abstract_t\">Qi WX, Fu S, Zhang Q, Guo XM. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis. BMC Med 2014; 12:203.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/60\" class=\"nounderline abstract_t\">Burtness B, Anadkat M, Basti S, et al. NCCN Task Force Report: Management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer. J Natl Compr Canc Netw 2009; 7 Suppl 1:S5.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/61\" class=\"nounderline abstract_t\">Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/62\" class=\"nounderline abstract_t\">Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007; 21:34.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/63\" class=\"nounderline abstract_t\">Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol 2012; 67:1025.</a></li><li class=\"breakAll\">Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 28, 2018).</li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/65\" class=\"nounderline abstract_t\">Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol 2007; 25:5121.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/66\" class=\"nounderline abstract_t\">Balagula Y, Garbe C, Myskowski PL, et al. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol 2011; 50:129.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/67\" class=\"nounderline abstract_t\">Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. Br J Dermatol 2011; 165:1337.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/68\" class=\"nounderline abstract_t\">Mah&eacute; E, Morelon E, Lechaton S, et al. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol 2006; 55:139.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/69\" class=\"nounderline abstract_t\">Campistol JM, de Fijter JW, Flechner SM, et al. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transplant 2010; 24:149.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/70\" class=\"nounderline abstract_t\">Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008; 13:1001.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/71\" class=\"nounderline abstract_t\">Balagula Y, Barth Huston K, Busam KJ, et al. Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Invest New Drugs 2011; 29:1114.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/72\" class=\"nounderline abstract_t\">Potthoff K, Hofheinz R, Hassel JC, et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 2011; 22:524.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/73\" class=\"nounderline abstract_t\">Segaert S, Tabernero J, Chosidow O, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 2005; 3:599.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/74\" class=\"nounderline abstract_t\">Eaby B, Culkin A, Lacouture ME. An interdisciplinary consensus on managing skin reactions associated with human epidermal growth factor receptor inhibitors. Clin J Oncol Nurs 2008; 12:283.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/75\" class=\"nounderline abstract_t\">Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008; 19:142.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/76\" class=\"nounderline abstract_t\">Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009; 16:16.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/77\" class=\"nounderline abstract_t\">Santini D, Vincenzi B, Guida FM, et al. Aprepitant for management of severe pruritus related to biological cancer treatments: a pilot study. Lancet Oncol 2012; 13:1020.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/78\" class=\"nounderline abstract_t\">Mir O, Coriat R. Aprepitant for pruritus: drug-drug interactions matter. Lancet Oncol 2012; 13:964.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/79\" class=\"nounderline abstract_t\">Porzio G, Aielli F, Verna L, et al. Efficacy of pregabalin in the management of cetuximab-related itch. J Pain Symptom Manage 2006; 32:397.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/80\" class=\"nounderline abstract_t\">Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 2011; 19:1079.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/81\" class=\"nounderline abstract_t\">Thatcher N, Nicolson M, Groves RW, et al. Expert consensus on the management of erlotinib-associated cutaneous toxicity in the u.k. Oncologist 2009; 14:840.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/82\" class=\"nounderline abstract_t\">Gutzmer R, Becker JC, Enk A, et al. Management of cutaneous side effects of EGFR inhibitors: recommendations from a German expert panel for the primary treating physician. J Dtsch Dermatol Ges 2011; 9:195.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/83\" class=\"nounderline abstract_t\">Pinto C, Barone CA, Girolomoni G, et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011; 16:228.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/84\" class=\"nounderline abstract_t\">Gerber PA, Meller S, Eames T, et al. Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. Eur J Med Res 2012; 17:4.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/85\" class=\"nounderline abstract_t\">Requena C, Llombart B, Sanmart&iacute;n O. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin. Cutis 2012; 90:77.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/86\" class=\"nounderline abstract_t\">DeWitt CA, Siroy AE, Stone SP. Acneiform eruptions associated with epidermal growth factor receptor-targeted chemotherapy. J Am Acad Dermatol 2007; 56:500.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/87\" class=\"nounderline abstract_t\">Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005; 153:849.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/88\" class=\"nounderline abstract_t\">Scope A, Agero AL, Dusza SW, et al. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007; 25:5390.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/89\" class=\"nounderline abstract_t\">Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28:1351.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/90\" class=\"nounderline abstract_t\">Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008; 113:847.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/91\" class=\"nounderline abstract_t\">Deplanque G, Chavaillon J, Vergnenegre A. CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients. J Clin Oncol 2010; 28:640s.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/92\" class=\"nounderline abstract_t\">Bachet JB, Peuvrel L, Bachmeyer C, et al. Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 2012; 17:555.</a></li><li><a href=\"https://www.uptodate.com/contents/acneiform-eruption-secondary-to-epidermal-growth-factor-receptor-egfr-inhibitors/abstract/93\" class=\"nounderline abstract_t\">Petrelli F, Borgonovo K, Cabiddu M, et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysis. Br J Dermatol 2016; 175:1166.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 15764 Version 12.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H195039241\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H195039099\" id=\"outline-link-H195039099\">INTRODUCTION</a></li><li><a href=\"#H195039106\" id=\"outline-link-H195039106\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3612236\" id=\"outline-link-H3612236\">Risk factors</a></li><li><a href=\"#H31702946\" id=\"outline-link-H31702946\">Relationship between rash and survival</a></li></ul></li><li><a href=\"#H195039113\" id=\"outline-link-H195039113\">PATHOGENESIS</a><ul><li><a href=\"#H195039120\" id=\"outline-link-H195039120\">Direct receptor inhibition</a></li><li><a href=\"#H195039127\" id=\"outline-link-H195039127\">Inflammatory response</a></li><li><a href=\"#H195039134\" id=\"outline-link-H195039134\">Role of microorganisms</a></li></ul></li><li><a href=\"#H3612515\" id=\"outline-link-H3612515\">HISTOPATHOLOGY</a></li><li><a href=\"#H195039141\" id=\"outline-link-H195039141\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H3611686\" id=\"outline-link-H3611686\">CLINICAL COURSE</a></li><li><a href=\"#H699849676\" id=\"outline-link-H699849676\">COMPLICATIONS AND SEQUELAE</a><ul><li><a href=\"#H699849684\" id=\"outline-link-H699849684\">Secondary infection</a></li><li><a href=\"#H699849441\" id=\"outline-link-H699849441\">Cutaneous sequelae</a></li><li><a href=\"#H699849637\" id=\"outline-link-H699849637\">Impact on patients&rsquo; quality of life</a></li></ul></li><li><a href=\"#H195039162\" id=\"outline-link-H195039162\">DIAGNOSIS</a><ul><li><a href=\"#H3612688\" id=\"outline-link-H3612688\">Clinical</a></li><li><a href=\"#H195039171\" id=\"outline-link-H195039171\">Grading of severity</a></li></ul></li><li><a href=\"#H195039178\" id=\"outline-link-H195039178\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H195039192\" id=\"outline-link-H195039192\">MANAGEMENT</a><ul><li><a href=\"#H29755924\" id=\"outline-link-H29755924\">General principles</a></li><li><a href=\"#H699849803\" id=\"outline-link-H699849803\">Treatment of pruritus</a></li><li><a href=\"#H29755685\" id=\"outline-link-H29755685\">Patients with grade 1 rash</a></li><li><a href=\"#H29755709\" id=\"outline-link-H29755709\">Patients with grade 2 rash</a></li><li><a href=\"#H662500\" id=\"outline-link-H662500\">Patients with grade &ge;3 rash</a><ul><li><a href=\"#H27163434\" id=\"outline-link-H27163434\">- Refractory grade &ge;3 rash</a></li></ul></li></ul></li><li><a href=\"#H52639361\" id=\"outline-link-H52639361\">PREVENTION</a><ul><li><a href=\"#H52639369\" id=\"outline-link-H52639369\">General measures</a></li><li><a href=\"#H52639376\" id=\"outline-link-H52639376\">Preemptive therapy</a></li></ul></li><li><a href=\"#H195039241\" id=\"outline-link-H195039241\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/15764|ALG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"ALGORITHMS\">ALGORITHMS</a></div><ul><li><a href=\"image.htm?imageKey=DERM/87010\" class=\"graphic graphic_algorithm\">- EGFR inhbtr acneiform rash treatment</a></li></ul></li><li><div id=\"DERM/15764|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PC/55753\" class=\"graphic graphic_picture\">- EGFR inhibitor acneiform erupt</a></li><li><a href=\"image.htm?imageKey=DERM/86994\" class=\"graphic graphic_picture\">- Steroid acne 1</a></li><li><a href=\"image.htm?imageKey=DERM/86995\" class=\"graphic graphic_picture\">- Steroid acne 2</a></li><li><a href=\"image.htm?imageKey=DERM/86998\" class=\"graphic graphic_picture\">- Pityrosporum folliculitis 2</a></li><li><a href=\"image.htm?imageKey=DERM/86997\" class=\"graphic graphic_picture\">- Pityrosporum folliculitis 1</a></li><li><a href=\"image.htm?imageKey=DERM/86999\" class=\"graphic graphic_picture\">- Tinea barbae 1</a></li><li><a href=\"image.htm?imageKey=DERM/87000\" class=\"graphic graphic_picture\">- Tinea barbae 2</a></li><li><a href=\"image.htm?imageKey=DERM/60102\" class=\"graphic graphic_picture\">- Dermatophyte potassium hydroxide</a></li><li><a href=\"image.htm?imageKey=DERM/54404\" class=\"graphic graphic_picture\">- Eosinophilic folliculitis B</a></li><li><a href=\"image.htm?imageKey=DERM/87125\" class=\"graphic graphic_picture\">- HIV-associated eosinophilic folliculitis</a></li><li><a href=\"image.htm?imageKey=PC/78005\" class=\"graphic graphic_picture\">- Eosinophilic folliculitis histology low power view</a></li><li><a href=\"image.htm?imageKey=PC/67192\" class=\"graphic graphic_picture\">- Eosinophilic folliculitis histology</a></li></ul></li><li><div id=\"DERM/15764|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/67786\" class=\"graphic graphic_table\">- NCI CTCAE v5 acneiform rash</a></li><li><a href=\"image.htm?imageKey=PC/60541\" class=\"graphic graphic_table\">- Fitzpatrick skin phototypes</a></li><li><a href=\"image.htm?imageKey=PC/76762\" class=\"graphic graphic_table\">- Causes drug induced acne</a></li><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-conventional-chemotherapy-agents\" class=\"medical medical_review\">Cutaneous side effects of conventional chemotherapy agents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=dermatophyte-tinea-infections\" class=\"medical medical_review\">Dermatophyte (tinea) infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hiv-associated-eosinophilic-folliculitis\" class=\"medical medical_review\">HIV-associated eosinophilic folliculitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=invasive-malassezia-infections\" class=\"medical medical_review\">Invasive Malassezia infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=laser-and-light-therapy-for-cutaneous-vascular-lesions\" class=\"medical medical_review\">Laser and light therapy for cutaneous vascular lesions</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oral-isotretinoin-therapy-for-acne-vulgaris\" class=\"medical medical_review\">Oral isotretinoin therapy for acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-acne-vulgaris\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of acne vulgaris</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pruritus-overview-of-management\" class=\"medical medical_review\">Pruritus: Overview of management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-acne-vulgaris\" class=\"medical medical_review\">Treatment of acne vulgaris</a></li></ul></div></div>","javascript":null}